Citigroup Inc Mersana Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 82,312 shares of MRSN stock, worth $170,385. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,312

Previous 25,566 221.96%

Holding current value

$170,385

Previous $51,000 203.92%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.23 - $2.25 $69,797 - $127,678	56,746 Added 221.96%	82,312 $155,000
Q2 2024 Aug 12, 2024	SELL	$2.0 - $4.45 $778,564 - $1.73 Million	-389,282 Reduced 93.84%	25,566 $51,000
Q1 2024 May 10, 2024	BUY	$2.16 - $5.94 $861,567 - $2.37 Million	398,874 Added 2497.02%	414,848 $1.86 Million
Q4 2023 Feb 09, 2024	BUY	$1.11 - $2.34 $15,805 - $33,319	14,239 Added 820.69%	15,974 $37,000
Q3 2023 Nov 09, 2023	SELL	$1.06 - $3.91 $131,326 - $484,421	-123,893 Reduced 98.62%	1,735 $2,000
Q2 2023 Aug 10, 2023	SELL	$3.08 - $9.55 $904,423 - $2.8 Million	-293,644 Reduced 70.04%	125,628 $413,000
Q1 2023 May 11, 2023	BUY	$4.0 - $7.02 $903,200 - $1.59 Million	225,800 Added 116.71%	419,272 $1.72 Million
Q4 2022 Feb 09, 2023	SELL	$5.65 - $7.86 $21,498 - $29,907	-3,805 Reduced 1.93%	193,472 $1.13 Million
Q3 2022 Nov 10, 2022	BUY	$4.63 - $8.0 $868,949 - $1.5 Million	187,678 Added 1955.18%	197,277 $1.33 Million
Q2 2022 Aug 10, 2022	BUY	$2.84 - $5.0 $9,204 - $16,205	3,241 Added 50.98%	9,599 $44,000
Q1 2022 May 12, 2022	SELL	$3.74 - $6.63 $825,320 - $1.46 Million	-220,674 Reduced 97.2%	6,358 $25,000
Q4 2021 Feb 10, 2022	BUY	$5.48 - $9.86 $622,971 - $1.12 Million	113,681 Added 100.29%	227,032 $1.41 Million
Q3 2021 Nov 10, 2021	BUY	$8.56 - $14.47 $970,284 - $1.64 Million	113,351 New	113,351 $1.07 Million

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $201M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account